|Bid||6.68 x 0|
|Ask||7.76 x 0|
|Day's range||7.26 - 7.40|
|52-week range||6.82 - 11.33|
|Beta (5Y monthly)||1.19|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Teva Pharmaceutical Industries on Wednesday agreed to pay Nevada $193 million to settle claims that its marketing practices fueled opioid addiction, the state announced. Nevada was one of two states, along with New Mexico, that did not join a $4.35 billion nationwide settlement with the Israel-based drugmaker last year. "The money coming into Nevada from these settlements will help our state recover and will help resources flow to the Nevadans impacted by this epidemic," Nevada Attorney General Aaron Ford said in a statement.
On May 18, Teva Pharmaceuticals (NYSE: TEVA) announced that it was planning to execute a strategic pivot that would return the company to growth after a long period of stagnation. Between the upcoming fruits of its biosimilar generic medicines pipeline and its anticipated investments in expanding its pipeline assets, management is hoping to mark a turnaround point within the next few years and meet its financial targets for 2027. Generally, generic drug manufacturers are companies that enjoy stable demand for cheaper copies of critical medicines.
Generally speaking long term investing is the way to go. But no-one is immune from buying too high. For example the...
Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were jumping 5.7% as of 11:21 a.m. ET on Thursday. Francis maintained that focusing on these four areas will enable Teva to "gain momentum as a stronger, bolder, and simpler organization." At least one Wall Street analyst seemed to be convinced that Teva could now be on the right track.
The U.S. Supreme Court on Monday declined to hear Teva Pharmaceuticals USA Inc's challenge to a $235 million award to GlaxoSmithKline LLC in a patent dispute over generic drugs involving a heart medication. The justices turned away Israel-based Teva's appeal of a lower court's ruling reinstating the jury award for U.K.-based GSK. The case involves "skinny labels," which allow generic drugmakers to avoid patent lawsuits if a generic drug's label omits potentially infringing uses of a brand-name drug.
TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.
Additional information regarding these statements and our non-GAAP financial measures is available on our earning release and in our SEC Forms 10-K and 10-Q. To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's Q1 2023 results and business performance, recent events, and priorities going forward. Joining Richard and Eli on the call today are Sven Dethlefs, Teva's head of North America business; and Dr. Eric Hughes, our head of R&D and chief medical officer.
While the top- and bottom-line numbers for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Embecta's (EMBC) diabetes care business is expected to have progressed in the fiscal second quarter banking on strong execution of its three strategic pillars.
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.
Many investors have had the unpleasant experience of buying shares of a company they thought was safe, only to see their money evaporate down the line when their investment wasn't as "safe" as their initial impressions. In that vein, one of the hallmarks of safety is reliable and highly recurring revenue and earnings, complete with a durable and defensible profit margin that's consistent over time. Manufacturers of generic pharmaceuticals seem to fit that bill.
Alvotech's shares decline as it receives a complete response letter for biosimilar candidate, AVT02, treating autoimmune disorders.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.
Shares of Emergent (EBS) have been rising following the FDA's approval to an OTC version of its Narcan nasal spray.
The Biden Administration told the U.S. Supreme Court on Wednesday that it should agree to hear a patent appeal over drug labels involving Teva Pharmaceuticals USA Inc and GlaxoSmithKline LLC that could have significant ramifications for the generic-drug industry. The U.S. Solicitor General said Teva's generic version of GSK's heart drug Coreg could not have violated GSK's patent rights because Teva omitted the infringing use of the drug from its labeling. Such "skinny labels" typically allow generic drugmakers to launch their products earlier while avoiding liability for infringing brand-name drugmakers' patents.
Key Insights Given the large stake in the stock by institutions, Teva Pharmaceutical Industries' stock price might be...
As much as we'd enjoy a stock market that never declined, stocks can and do move in both directions. Last year, all three major U.S. stock indexes tumbled into respective bear markets and produced their worst returns since the financial crisis. Despite 39 official stock market corrections in the benchmark S&P 500 since the beginning of 1950, all but the current decline eventually gave way to a bull market rally that took the broader market to new highs.
Teva Pharmaceutical Industries (NYSE: TEVA) and Viatris (NASDAQ: VTRS) are two of the top makers of generic pharmaceuticals, but both healthcare companies are having to look beyond their generic and branded drugs to find a way to grow sales. While Teva's 2022 revenue was down compared to 2021, the company is forecasting revenue growth in 2023, due in part to increased sales of anti-spasm drug Austedo, as well as a likely launch of a Humira biosimilar. Viatris' revenue was also down in 2022, but its net income was up and it is expecting more than $500 million in revenue from new launches this year.
TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.
Additional information regarding these statements and our non-GAAP financial measures is available on our earnings release and in our SEC Form 10-K and 10-Q. To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's 2022 results and business performance, recent events, and priorities going forward. Joining Richard and Eli on the call today is Sven Dethlefs, head of North America business, who will be available during the question-and-answer session that will follow the presentation.
Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were sliding 5.4% lower as of 11:47 a.m. ET on Wednesday. The decline came after the drugmaker announced its 2022 full-year and fourth-quarter results. Teva reported fourth-quarter revenue of $3.88 billion, down 5% year over year.
These profitable companies are exceptionally cheap and ripe for the picking, following a 33% decline in the Nasdaq Composite.